The GLP-1 Market in 2026: Who Wins the Next Phase of Metabolic Dominance?

The GLP-1 and broader metabolic therapeutics category has moved beyond breakthrough momentum into structural competition.

What was once defined by supply constraints and percentage weight loss is now shaped by pricing pressure, payer engineering, manufacturing scale, lifecycle strategy and next-generation platform differentiation. The next phase of this market will not be won on efficacy alone - but on durability, access, and strategic execution.

This article provides a strategic overview of the GLP-1 landscape as of February 2026, based on publicly available company disclosures, regulatory communications and reported data. Given the pace of clinical and commercial developments in this space, it reflects the market at a defined point in time rather than ongoing daily updates.

Executive Summary

As of February 2026, the GLP-1 and broader obesity therapeutics market has transitioned from a supply-constrained hypergrowth phase into a structurally embedded, strategically complex global category.

The 2023–2024 period was defined by unprecedented demand acceleration and manufacturing bottlenecks. By contrast, 2025–early 2026 marks the beginning of a new phase characterised by:

Commercial scale and fulfilment reliability as competitive weapons

Payer access engineering and reimbursement scrutiny

Regulatory tightening around compounded GLP-1 supply

Lifecycle expansion into cardiometabolic, renal and hepatic outcomes

Next-generation mechanisms (dual/triple agonists, extended-interval dosing, oral small molecules, RNA-based approaches)

Accelerating cross-border licensing, particularly from China-origin innovators

Market leaders Novo Nordisk and Eli Lilly remain dominant revenue engines. However, the competitive narrative is increasingly shaped by:

Late-stage entrants (Amgen, Viking, Pfizer via Metsera)

Oral and small-molecule challengers (Structure Therapeutics and others)

Platform originators such as Zealand Pharma

China-linked portfolio builders (Innovent, Verdiva Bio, Hansoh)

Emerging non-GLP mechanisms targeting body composition, metabolic durability and combination therapy strategies (Antag Therapeutics, Wave, Melio Bio)

The category has now moved beyond “percentage weight loss” toward a more sophisticated value framework centred on:

Durability and long-term adherence

Tolerability and discontinuation rates

Cardiometabolic and liver outcomes

Lean mass preservation

Maintenance therapy positioning

Real-world economic sustainability

State of the Market – Key Themes (2025–Early 2026)

1. Commercial Scale & Revenue Concentration

The GLP-1 market remains highly concentrated, with two dominant commercial leaders accounting for the majority of global branded sales.

Novo Nordisk and Eli Lilly continue to generate multi-billion-dollar quarterly revenues from semaglutide and tirzepatide franchises.

Obesity has shifted from “emerging category” to structural earnings pillar.

International expansion across Europe, Asia-Pacific and select emerging markets remains ongoing.

Supply stability has restored continuity-of-therapy as a core KPI.

However, concentration creates strategic vulnerability:
As Phase 3 competitors advance and oral options mature, payer leverage is likely to increase.

2. Access, Pricing & Reimbursement Pressure

The payer environment is now the primary commercial battleground.

Key developments include:

Employer and PBM utilisation management tightening

Expanded step-edit protocols

Increasing scrutiny of cash-pay channels

Growing Medicare/Medicaid exposure via diabetes-linked utilisation

Continued debate over obesity-specific long-term reimbursement policy

The long-term sustainability of current pricing structures remains uncertain.
Net price compression is likely over 2026–2028, particularly in mature US markets.

3. Regulatory & Compounding Developments

With national shortages easing in 2025, regulators clarified that certain GLP-1 shortages had resolved.

Consequences:

Reduced permissiveness for compounding under shortage exemptions

Legal action by branded manufacturers against telehealth distributors of compounded semaglutide

Transition from supply emergency to IP enforcement phase

This materially shifts risk exposure for telehealth and grey-market supply chains.

4. Science & Differentiation – Beyond Weekly Weight Loss

The next wave of differentiation includes:

Monthly or extended-interval dosing

Oral small-molecule GLP-1 receptor agonists

Dual and triple agonists (GLP-1/GIP, GLP-1/glucagon)

Lean mass preservation strategies

Visceral fat targeting

RNA-based metabolic modulation

MASH (liver) and cardiometabolic expansion

The competitive battlefield is transitioning from “first-generation GLP-1s” to “metabolic platform competition.”

5. Manufacturing & Distribution

Manufacturing remains strategically material.

Peptide injectables:

Require complex fill-finish, pen device assembly, cold chain logistics.

Oral small molecules:

Offer theoretical distribution and cost advantages.

Could reshape payer economics if efficacy holds.

Continuity, fulfilment reliability and supply redundancy now represent commercial differentiators.

6. China’s Expanding Influence

China-origin innovation is no longer peripheral.

China-based companies are:

Advancing dual-mechanism candidates at speed

Achieving domestic regulatory approvals

Licensing assets into Western pipelines

Offering capital-efficient R&D platforms

Cross-border licensing is accelerating, with Western biotech increasingly sourcing innovation from China-origin programs.

7. Funding, Partnering & M&A

2025–2026 highlights:

Pfizer’s acquisition of Metsera to re-enter obesity

Large Series A financings (e.g., Verdiva Bio)

Continued speculation around Viking and other Phase 2/3 companies

Strategic partnering by Zealand Pharma

For smaller biotech companies, the strategic dilemma remains:

Advance independently through Phase 3 - or secure earlier liquidity via partnership or acquisition.

Company Profiles

(Ordered by Commercial Status and Development Stage)

I. Companies with Marketed GLP-1 / Incretin Products

Novo Nordisk

Marketed Portfolio

Ozempic (weekly injectable, diabetes)

Wegovy (weekly injectable, obesity)

Rybelsus (daily oral semaglutide)

Commercial Scale

Novo Nordisk remains the foundational architect of the obesity GLP-1 market.

Obesity and diabetes franchises now represent structural drivers of global revenue growth. Wegovy’s international expansion continues, while Ozempic remains embedded in diabetes care.

Novo Nordisk’s next-generation obesity candidate CagriSema (semaglutide + cagrilintide) failed to meet non-inferiority vs Eli Lilly’s Zepbound (tirzepatide) in a pivotal Phase 3 obesity trial, with ~23 % weight loss vs ~25.5 % for Zepbound. This result has been widely framed as a competitive setback for Novo’s leadership aspirations and has pressured the stock and strategic narrative around “next-gen incretin combos.”

Strategic Positioning

Novo operates a defensive leadership model built on:

Brand strength and outcomes evidence

Cardiovascular outcome expansion

Direct-to-patient channel optimisation

Structured access negotiations with payers

Legal enforcement against compounded supply

The company’s competitive focus has shifted from capacity expansion to lifecycle extension and market defence.

Strategic Risks

Net price erosion in the US

Payer restrictions in obesity-specific coverage

Oral and extended-interval challengers

Combination or body-composition-focused competitors

Eli Lilly

Marketed Portfolio

Mounjaro (tirzepatide; diabetes)

Zepbound (tirzepatide; obesity)

Commercial Scale

Lilly has emerged as Novo’s co-dominant rival, leveraging dual GIP/GLP-1 biology.

Obesity and diabetes now represent core pillars of Lilly’s revenue profile.

Strategic Positioning

Lilly’s commercial posture emphasises:

Aggressive category expansion

Access engineering and payer alignment

Therapy persistence management

International scaling

The dual-agonist positioning provides differentiation on efficacy narrative, but payer scrutiny remains intensifying.

Strategic Outlook

Lilly’s longer-term success depends on:

Expanding beyond injectables

Maintaining tolerability advantages

Defending net pricing power

Innovent Biologics (China)

Marketed Asset

Mazdutide (GLP-1/glucagon dual agonist; approved in China)

Strategic Significance

Innovent represents the first wave of China-based obesity innovation achieving domestic commercialisation.

Dual agonism positions mazdutide as part of next-generation metabolic evolution.

Strategic Outlook

Expansion within China

Potential cross-border partnering

Lifecycle development into broader metabolic indications

Sanofi

Position

Currently limited exposure in obesity incretins.

Strategic Outlook

Future participation likely via acquisition or partnership rather than organic innovation leadership.

II. Late-Stage (Phase 3) – No Commercial GLP-1 Revenue

Amgen

Lead Asset

MariTide (extended-interval GLP-1 biology; monthly or less frequent dosing)

Differentiation Strategy

Competes on:

Dosing convenience

Potential adherence advantage

Long-term durability framing

If adherence and persistence become primary payer metrics, extended-interval dosing may prove disruptive.

Risk Profile

Efficacy vs weekly incumbents

Tolerability at extended dosing intervals

Commercial differentiation in crowded Phase 3 field

Viking Therapeutics

Lead Asset

VK2735 (dual GLP-1/GIP; injectable and oral)

Strategic Thesis

Two parallel strategies:

Competitive injectable efficacy

Oral tablet as distribution and preference advantage

Strategic Optionality

Strong acquisition candidate if Phase 3 data remain competitive.

Pfizer (Post-Metsera Acquisition)

Strategic Re-Entry

Acquisition of Metsera re-establishes Pfizer’s presence in obesity.

Strategic Rationale

Portfolio rather than single-asset approach

Leverage global commercial infrastructure

Compete on differentiated next-gen candidates

Execution and differentiation will determine viability against entrenched leaders.

III. Phase 2 / Mid-Stage Entrants

Structure Therapeutics

Positioning

Oral small-molecule GLP-1 receptor agonist.

Strategic Value

If oral efficacy approaches injectable benchmarks, this could:

Reduce supply complexity

Broaden access

Improve adherence in maintenance settings

Key risk remains tolerability and discontinuation rates.

Altimmune

Lead Asset

Pemvidutide (GLP-1/glucagon dual agonist)

Strategic Edge

Obesity + liver (MASH) focus.

If successful, could command differentiated reimbursement positioning.

Hansoh (China)

Emerging metabolic pipeline participant with cross-border partnering potential.

Zealand Pharma

Strategic Role

Platform originator with major partnerships.

Key Program

Survodutide (licensed to Boehringer Ingelheim; GLP-1/glucagon dual agonist)

Strategic Significance

Zealand functions as a mechanism innovator and partner-scale originator.

Its future value is tied to:

Phase 3 differentiation

Expansion into MASH

Platform leverage across metabolic disease

Verdiva Bio

Overview

Clinical-stage cardiometabolic company launched with substantial Series A financing.

Built via licensing of multiple assets from China-based Sciwind.

Strategic Thesis

Portfolio strategy targeting:

Oral modalities

Maintenance therapy positioning

Chronic adherence optimisation

Market Role

Represents the capital-backed China-to-West acceleration model.

Execution risk centres on clinical differentiation in a crowded oral landscape.

IV. Early Clinical / Platform Innovation

Wave Life Sciences

RNA-based metabolic therapy platform targeting novel pathways.

Potential future role as combination backbone rather than standalone GLP-1 replacement.

PegBio

Early-stage GLP-1 development.

Likely relevance via regional or partnership pathways.

Antag Therapeutics

Mechanism

GIP receptor antagonism.

Strategic Differentiation

Positioned as complementary to GLP-1 therapy.

Potential combination therapy candidate.

Success depends on clinical validation of additive benefit.

Melio Bio

Positioning

Genetically validated cardiometabolic targets.

Focused on post-GLP-1 unmet needs:

Non-responders

Side effect reduction

Durability enhancement

Strategically positioned within next-generation combination ecosystem.

V. Potential Post-Exclusivity / Biosimilar Participants

Boehringer Ingelheim

Sun Pharma

Glenmark

Biocon

Teva

These companies may become relevant as patent cliffs approach.
However, Boehringer is already strategically engaged via survodutide partnership with Zealand.

Overall Market Outlook (2026–2028)

The GLP-1 category is expected to:

Continue global expansion

Experience pricing pressure in mature markets

See increased regulatory scrutiny

Undergo consolidation among Phase 2/3 biotech players

Differentiate increasingly on dosing interval, tolerability and durability

Expand cardiometabolic and liver indications

See greater China-origin participation

Encounter stronger employer and Medicare cost controls

The next 24 months will determine:

Which next-generation platforms meaningfully disrupt weekly injectable dominance — and whether the market fragments into multi-mechanism combination paradigms.

Sources & Methodology

This report is based on publicly available information as of February 2026, including:

Company annual reports (FY2025)

Q3/Q4 2025 earnings releases

Regulatory communications

Clinical trial registry disclosures

Corporate investor materials

Major financial press coverage

Currency conversions are based on average 2025 exchange rates where required.

Disclaimer

This report has been prepared by Elevate Pharma for informational and strategic discussion purposes only. While every effort has been made to ensure accuracy using publicly available information as of February 2026, Elevate Pharma makes no representation or warranty as to completeness or accuracy. Financial figures may reflect currency conversions and reported estimates. This document does not constitute investment advice, legal advice, medical advice, or a recommendation regarding any company or product.